Abstract: The present invention provides a process for manufacturing a multi-component product comprising at least two components cut from moving webs of material, registering the components with respect to one another, and depositing the registered components on a web of moving material. The components have respective leading and trailing edges, a longitudinal center line, and a longitudinal center defined by a point midway on said longitudinal center line between said leading and trailing edges.

Abstract: An absorbent article includes an absorbent pad and an outer cover. A release agent is applied to one of the outer surface of the absorbent pad and the inner surface of the outer cover. The release agent prevents at least a portion of the outer cover from adhering to the absorbent pad. In embodiments where the outer cover is extensible in a cross-direction and/or a longitudinal direction, the release agent prevents the absorbent pad from resisting mobility of the outer cover. Thus the absorbent pad has substantially no adhesion to the outer cover where the release agent is applied. Therefore, tearing of the absorbent pad and damage to, or release, of superabsorbent material from the absorbent pad during extension of the outer cover, is prevented. The release agent can be a silicon-active agent or a powder material having properties that prevent adhesion between adhesive and a forming tissue of the absorbent pad, or the outer cover.

Abstract: A class of .OMEGA.-substituted-1,4-benzoquinon-2-yl]alkanoic acids are useful in the treatment of chronic obstructive pulmonary disease (COPD). The preferred compound for the method of treatment is 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid or a pharmaceutically acceptable salt, ester or pro-drug thereof.

Abstract: A method of applying leg cuffs to a web including a bodyside, a cover, and an absorbent core therebetween including cutting leg cut-outs on opposite sides of the web, applying adhesive to the web adjacent the cut-outs or to a leg cuff material, placing the leg cuff material on a leg cuff applicator, cutting the leg cuffs material to make the leg cuffs, extending the length of the leg cuffs to be longer than the longitudinal length of the cut-outs, placing the extended leg cuffs over the cut-outs, and securing the leg cuffs to an outer surface of the web.

Abstract: An absorbent article, such as a sanitary napkin, is provided having an absorbent between a cover and a baffle. The absorbent article also includes an inwardly directed attachment panel adapted to be folded around at least a portion of the crotch of the undergarment. To facilitate ease of placing the sanitary napkin in an undergarment prior to use, the panel is held in an outward direction, relative to the longitudinal side of the absorbent, by a frangible securement bond. The frangible fastener is affixed to one surface of the panel and has a bond strength of less than about 500 grams. When the wearer is ready to secure the article in the undergarment, the bond is easily broken by the wearer and the panel is appropriately positioned.

Abstract: Polymer compositions of the invention typically comprise a base polymer composition, a polymer cleavage agent, and a stabilizer composition. The preferred base polymer composition comprises an ethylene vinyl alcohol copolymer composition. Preferred cleavage agent is an alkaline earth or transition metal salt, preferably an acetate, or a salt of an acid having 8 to 20 carbon atoms. The stabilizer composition comprises an alkylated phenol or bisphenol. Preferred stabilizer composition comprises a tocopherol, preferably alpha tocopherol.

Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.

Abstract: This invention pertains to a three dimensional garment and subassemblies of the garment. The garment has an elasticized leg and waist openings and is stretchable about the hip and stomach regions of a user. The garment provides superior fit about the legs especially in the crotch area.

Abstract: The invention relates to methods of applying adhesive to a lateral edge of a first web. The method includes transporting the first web along a first path and transporting a second web along a second path generally in surface-to-surface relationship with the first web at the lateral edge, with the second web extending outwardly from the first web. When adhesive is applied such as by spraying to the first web at the lateral edge, at least some adhesive passes outwardly of the lateral edge as overspray and is received by the second web. Thus, adhesive applied to the edge of the first web is received in combination by both of the first and second webs. Both of the first and second webs can be utilized in manufacturing articles. In some embodiments, adhesive is applied at both first and second lateral edges of the first web. In some embodiments, spaced leg cutouts are formed in lateral edges of the web.

Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.

Abstract: This invention pertains to metal-air electrochemical cells wherein one or more air entry ports is located in the bottom of the cathode can, to provide for entry of oxygen-rich air into the cathode can, where the oxygen participates in the chemical reaction whereby the cell produces electrical energy. In this invention, multiple small air entry ports are provided. Generally, the use of multiple ports distributed over the bottom of the cathode can, opposite the reaction surface of the cathode assembly, while not increasing the overall open area of the ports, results in an increase in the ratio of the cell limiting current to the rate at which moisture is lost from the cell. Accordingly, moisture loss as a function of electrical energy produced, is less.

Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.

Abstract: This invention pertains to draw tape equipment, and methods for incorporating draw tapes into plastic and like bags. In general, a continuous plastic web is slit at a slitting station to form layers, and respective free edges. The web then passes to a hole forming station where holes are punched in the top and bottom layers adjacent the free edges. After the holes are punched, edge regions of the top and bottom layers are separated from each other, followed by forming of hems in the separated layers at hem forming stations arranged in parallel with each other. Concurrent with forming of the hems, continuous draw tapes are fed to the hem forming stations and the hems are formed about the draw tapes. The formed hems, with the draw tapes incorporated therein, optionally pass through first temperature control stations where the temperature of the plastic web is controlled to a desired temperature before hem sealing. The formed hems are then sealed to the main bodies of the respective top and bottom layers.

Abstract: The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

Abstract: The present invention is directed to chemical processes for preparing 2-aryl-6-hydroxy-3-?4-(2-aminoethoxy)benzoyl!benzo?b!-thiophenes. The present invention is also directed to crystalline solvates and a non-solvated crystalline form of 6-hydroxy-2-(4-hydroxyphenyl)-3-?4-(2-piperidinoethoxy)benzoyl!-benzo?b!th iophene hydrochloride, as well as processes for their preparation.

Abstract: The present invention relates to compounds of formula I ##STR1## wherein R.sup.1 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), or --OSO.sub.2 (C.sub.4 -C.sub.6 alkyl);R.sup.2 is 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, benzothienyl, or --CH.sub.2 C.sub.6 H.sub.5 ; any of which may be optionally substituted with 1-3 substituents independently selected from the group halo, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), or --OSO.sub.2 (C.sub.4 -C.sub.6 alkyl);X is --CH.sub.2 --, --CO--, or --CH(OH)--;n is 2 or 3; andR.sup.3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides pharmaceutically active compounds of formula I ##STR1## wherein R.sup.1 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), or --OSO.sub.2 (C.sub.2 -C.sub.6 alkyl);R.sup.2 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), --OSO.sub.2 (C.sub.2 -C.sub.6 alkyl), or halo;R.sup.3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;n is 2 or 3; andz is --O-- or --S--;or a pharmaceutically acceptable salt thereof.Further provided are pharmaceutical compositions of compounds of formula I.

Abstract: The present invention provides processes for preparing compounds of formula I ##STR1## and for preparing compounds of formula VII ##STR2## Also provided are processes for preparing compounds of formula VII in addition to intermediates of formula IX ##STR3## wherein R.sup.1' is --OH, or --OR.sup.3, in which R.sup.3 is a hydroxy protecting group; andZ is bromo, iodo, triflate, or --B(OH).sub.2.

Abstract: The present invention provides useful intermediates for preparing 2-(substituted phenyl)benzothiophenes compounds said intermediates having the structure ##STR1## wherein R.sup.1 ' is --OH, or --OR.sup.3, in which R.sup.3 is a hydroxy protecting group; andZ is bromo, iodo, triflate, or --B(OH).sub.2 with the proviso that when Z is bromo or iodo, R1' is not alkoxy.

Abstract: The present invention provides a compound of formula I ##STR1## wherein R.sub.1 is H, OH, halo, OCO(C.sub.1 -C.sub.6 alkyl), OCO(aryl), OSO.sub.2 (C.sub.4 -C.sub.6 alkyl), OCOO(C.sub.1 -C.sub.6 alkyl), OCOO(aryl), OCONH (C.sub.1 -C.sub.6 alkyl), or OCON(C.sub.1 -C.sub.6 alkyl).sub.2 ;R.sub.2 is aryl, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, or 4-cyclohexanol;R.sub.3 is O(CH.sub.2).sub.2 or O(CH.sub.2).sub.3 ;R.sub.4 and R.sub.5 are optionally CO(CH.sub.2).sub.3,CO(CH.sub.2).sub.4, C.sub.1 -C.sub.6 alkyl, or R.sub.4 and R.sub.5 combine to form, with the nitrogen to which they are attached, piperidine, morpholine, pyrollidine, 3-methylpyrollidine, 3,3-dimethylpyrollidine, 3,4-dimethylpyrollidine, azepine, or pipecoline;R.sub.6 is>CH(C.sub.1 -C.sub.5 alkyl), >CH(C.sub.2 -C.sub.5 alkenyl), >C.dbd.CH(C.sub.1 -C.sub.5 alkyl), >CH(aryl), >C(OH)(C.sub.1 -C.sub.5 alkyl), >C(OH)(C.sub.2 -C.sub.5 alkenyl), C(OH)aryl;and phamaceutically acceptable salts thereof.